Stock GUD KNIGHT THERAPEUTICS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Insiders Knight Therapeutics Inc.

Equities

GUD

CA4990531069

Delayed Toronto S.E.
Other stock markets
 03:19:30 2024-04-29 pm EDT 		5-day change 1st Jan Change
5.76 CAD +0.52% Intraday chart for Knight Therapeutics Inc. -0.52% +10.98%
Mar. 22 Knight Therapeutics Price Target Raised to $7 at RBC MT
Mar. 21 Knight Therapeutics Reports Fourth Quarter Results MT

Insiders

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Knight Therapeutics Inc. Promotes Amal Khouri to Chief Business Officer
CI
Knight Therapeutics Inc. Appoints Samira Sakhia as Chief Executive Officer, Effective September 1, 2021
CI
Knight Therapeutics Inc. Announces Management Changes, Effective September 1, 2021
CI
Knight Therapeutics Inc. Announces Board Changes
CI
Knight Therapeutics Inc. Announces Management Changes
CI
Medison Biotech to Nominate 6 Directors for Knight Therapeutics' Board
CI
Knight Therapeutics Inc. Announces Board Changes
CI
Knight Therapeutics Inc. Announces Board Changes
CI
Knight Therapeutics Inc. Appoints Samira Sakhia as President and Member of the Board of Directors
CI
Knight Therapeutics Inc. Announces Board Changes
CI
Knight Therapeutics Inc. Announces Board Change
CI
Knight Therapeutics Inc. Announces Executive Appointments
CI
Knight Therapeutics Inc. Announces Executive Appointments
CI
Knight Therapeutics Inc. Announces Resignation of Mark A. Beaudet from the Board of Directors
CI
Knight Therapeutics Inc. Appoints Jeffrey Kadanoff as New CFO
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. GUD Stock
  4. News Knight Therapeutics Inc.
  5. Insiders